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Endothelial destabilization by angiopoietin-2
via integrin b1 activation
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Angiopoietins regulate vascular homeostasis via the endothelial Tie receptor tyrosine kinases.
Angiopoietin-1 (Ang1) supports endothelial stabilization via Tie2 activation. Angiopoietin-2
(Ang2) functions as a context-dependent Tie2 agonist/antagonist promoting pathological
angiogenesis, vascular permeability and inﬂammation. Elucidating Ang2-dependent
mechanisms of vascular destablization is critical for rational design of angiopoietin
antagonists that have demonstrated therapeutic efﬁcacy in cancer trials. Here, we report that
Ang2, but not Ang1, activates b1-integrin, leading to endothelial destablization. Autocrine
Ang2 signalling upon Tie2 silencing, or in Ang2 transgenic mice, promotes b1-integrin-
positive elongated matrix adhesions and actin stress ﬁbres, regulating vascular endothelial-
cadherin-containing cell–cell junctions. The Tie2-silenced monolayer integrity is rescued by
b1-integrin, phosphoinositide-3 kinase or Rho kinase inhibition, and by re-expression of a
membrane-bound Tie2 ectodomain. Furthermore, Tie2 silencing increases, whereas Ang2
blocking inhibits transendothelial tumour cell migration in vitro. These results establish Ang2-
mediated b1-integrin activation as a promoter of endothelial destablization, explaining the
controversial vascular functions of Ang1 and Ang2.
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A
ngiopoietin growth factors, in addition to vascular
endothelial growth factors (VEGFs), are critical regulators
of vascular development, tissue homeostasis and
pathological angiogenic responses1,2. Angiopoietin-1 (Ang1)
mediates its vascular-stabilizing and anti-inﬂammatory effects
by activating the endothelial Tie2 receptor3–5, while angiopoietin-
2 (Ang2) is a weak Tie2 agonist whose activity is context
dependent6,7. Ang2 levels, normally constrained during
homeostasis, are elevated in endothelial cells during vessel
remodelling, particularly in the tumour vasculature and in
diseases associated with increased vascular permeability and
endothelial dysfunction, such as sepsis and acute lung injury8,9. In
addition to the increased Ang2/Ang1 ratio, decreased Tie2 levels
have been reported in sepsis10,11. Such changes likely shift
Ang1–Tie2 signalling in endothelial cell–cell junctions towards
Ang2 signalling, thereby reducing Tie2 phosphorylation and
priming the endothelium for inﬂammatory cytokine signals,
permeability and vascular destablization12–14. Under these
conditions, Ang2-blocking antibodies show beneﬁcial vascular-
stabilizing effects, demonstrating the critical role of Ang2
in processes leading to compromised vascular architecture15,16.
Ang2-blocking antibodies inhibit also tumour growth, tumour
angiogenesis, as well as metastasis to lymph nodes and lungs17–19.
In lung metastases, Ang2 inhibition improved, while transgenic
endothelial Ang2 expression decreased capillary integrity,
indicating that blocking Ang2 inhibits metastatic dissemination,
in part, by enhancing the integrity of endothelial cell–cell
junctions19. During vascular development, Ang2 inhibition
blocked VE-cadherin phosphorylation at tyrosine residue 685
and the concomitant formation of button-like junctions in initial
lymphatic vessels20. Transgenic expression of Ang2 in mouse
embryos induced severe vascular abnormalities, including a
discontinuous vascular network and collapsed endocardial
lining of the heart6. These defects phenocopied those found in
embryos lacking Tie2 or Ang1, indicating that Ang2 counteracted
vascular stability promoted by Ang1–Tie2 signalling3,6,21.
However, the vessel discontinuities caused by Ang2
overexpression were more severe than in Ang1 or Tie2 gene-
targeted embryos, suggesting that Ang2 may have additional
functions besides inhibiting the Ang1–Tie2 signals6.
Integrins, which regulate endothelial cell–cell and cell–matrix
interactions, have been identiﬁed as alternative receptors for the
angiopoietins in certain Tie2-negative non-endothelial cells22–25,
and in the endothelial tip cells of angiogenic vessel sprouts, which
express low levels of Tie2 (refs 26,27). However, it remains
unknown whether Ang1 and Ang2 differentially regulate integrin
signalling, and whether integrins are involved in Ang2-induced
endothelial destabilization. Here we report that Ang2, but not
Ang1, directly activates b1-integrin. Autocrine Ang2 signalling in
Tie2-silenced endothelial cells and in the Ang2 transgenic mice,
which show reduced Tie2 localization in the endothelial cell–cell
junctions, promotes changes in the cytoskeleton, matrix adhesion
and cell junctions that lead to reduced cell–cell adhesion. These
results suggest that Ang2, via b1-integrin activation, may
predispose vessels to endothelial destablization.
Results and Discussion
Tie2 silencing reduces endothelial monolayer integrity. To
investigate the function of endothelial cell-secreted Ang2 on
endothelial integrity, we silenced Ang2, Tie2 or the related Tie1
receptor in human dermal blood microvascular endothelial cells
(BECs), which secrete endogenous Ang2 stored in Weibel–Palade
bodies28. In BECs transduced with scrambled (Scr) control short
hairpin RNA (shRNA) lentivirus (Fig. 1a) and in non-transduced
BECs (Supplementary Fig. 1b), actin formed a peripheral cortical
structure, which stabilizes endothelial cell–cell junctions and
monolayer integrity29. Tie2 silencing (shTie2) induced an
elongated cell morphology, loss of the cortical actin rim and led
to the formation of prominent actin stress ﬁbres extending across
the cell body (Fig. 1a–c; Supplementary Fig. 1). In contrast, Ang2
or Tie1 silencing had minimal effects on the cortical actin
cytoskeleton (Fig. 1g,i; Supplementary Fig. 1a,c). In line with the
known role of actin stress ﬁbres in generating a centripetal
tension that weakens endothelial cell–cell junctions30, the
adherens junction proteins VE-cadherin and b-catenin were
reduced in the cell–cell contacts of Tie2-silenced BECs and
human pulmonary microvascular endothelial cells (Fig. 1a,d;
Supplementary Fig. 2a,b). Importantly, Tie2 silencing reduced
cell surface VE-cadherin more than total VE-cadherin
(Supplementary Fig. 2c). However, the tight junction protein
ZO-1 was not affected by Tie2 silencing (Supplementary Fig. 2d).
We recently reported that Ang2-blocking antibodies improve
the integrity of endothelial cell–cell junctions in the lungs of
tumour-bearing mice, thereby contributing to reduced pulmonary
metastasis in mouse models19. To test whether Ang2 was directly
involved in the regulation of transendothelial tumour cell
migration, we employed BEC monolayers grown on Transwell
inserts. Ang2-blocking antibodies, targeting the Ang2–Tie2
interaction, inhibited the migration of ﬂuorescently labelled
human lung carcinoma (LNM-35) cells across the endothelial cell
monolayer, but did not affect Ang2 secretion by BECs, or LNM-
35 cell migration in the absence of endothelial cells (Fig. 1e;
Supplementary Fig. 2e,f). In contrast, the Tie2-silenced endo-
thelium was signiﬁcantly more permissive for transmigration of
green ﬂuorescent protein (GFP)-tagged murine Lewis lung
carcinoma (LLC) cells than the control-transduced endothelium
(Fig. 1f), indicating a compromised endothelial barrier in the
absence of Tie2, in line with the observed decrease in
adherens junction proteins in the Tie2-silenced cells (Fig. 1a,d;
Supplementary Fig. 2a,b).
Ang2 regulates endothelial integrity independently of Tie2.
Ang2 is the only Tie2 ligand expressed to signiﬁcant levels in
BECs according to results of messenger RNA proﬁling and
quantitative reverse transcription (Q-RT)–PCR (Ang1/Tie2 ratio
0.01; Ang2/Tie2 ratio 6.8 (ref. 31); Fig. 1h). We envisioned that
Ang2 signalling may be deregulated upon silencing of its receptor
Tie2, leading to altered cellular architecture and increased tumour
cell migration; we therefore simultaneously silenced Tie2 and
Ang2 in the BECs. The alterations in actin architecture (that is,
loss of cortical actin and the formation of prominent actin stress
ﬁbres) following Tie2 silencing were rescued upon Ang2þTie2
double silencing (Fig. 1g,i; Supplementary Fig. 2g). These data
indicated that endothelial Ang2 stimulates stress ﬁbre formation
via a Tie2-independent mechanism.
Ang2 regulates b1-integrin activation in Tie2-silenced cells.
Integrins, which are known to regulate endothelial cell–cell
adhesion by the reorganization of the cell cytoskeleton32, have
been previously reported to interact with angiopoietin–Tie2
receptor complexes33,34 and to function as alternative receptors
for angiopoietins23–25,27. As BECs express high levels of both b1-
and a5-integrins, which function as an a5b1 heterodimer to
efﬁciently bind RGD-containing ﬁbronectin, we ﬁrst investigated
whether b1-integrin activity was altered in the Tie2-silenced cells
by using b1-integrin activation-state-speciﬁc antibodies (12G10
and 9EG7). In BECs growing on ﬁbronectin, active b1-integrin
was localized in focal adhesions in the cell periphery close to the
cell–cell junctions (Fig. 2a; Supplementary Fig. 3a). However, in
the Tie2-silenced BECs, active b1-integrin was detected centrally
and across the cell body in prominent, elongated adhesion
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structures, resembling ﬁbrillar adhesions, indicative of increased
cell retraction and altered substrate adhesion sites (Fig. 2a;
Supplementary Fig. 3a). Furthermore, during cell spreading
on ﬁbronectin, we noted markedly enhanced generation of
centrally located, active b1-integrin-containing adhesions in
the Tie2-silenced cells, when compared with Scr-transduced
cells (Fig. 2b,c; Supplementary Fig. 4). When both Tie2
and Ang2 were silenced in BECs the formation of the
b1-integrin-positive elongated adhesions was inhibited,
indicating that Ang2 was required for the increased b1-integrin
activation in the cell centre (Fig. 2a).
Integrin a5b1 is involved in extracellular matrix deposition by
endothelial cells35. Rho kinase-mediated stress ﬁbre formation
and traction forces promote the translocation of ﬁbronectin-
bound a5b1 integrins towards the cell body, enabling the
unfolding of ﬁbronectin cryptic sites and ﬁbrillogenesis36. We
therefore tested whether ﬁbronectin remodelling was altered in
the Tie2-silenced cells. Control cells, cultured on vitronectin in
ﬁbronectin-depleted growth medium, generated a dense network
of ﬁbrillar ﬁbronectin, whereas the Tie2-silenced cells produced
straight and parallel short ﬁbronectin ﬁbres aligned along the
direction of the actin stress ﬁbres (Fig. 2d), suggesting that
increased b1-integrin activity altered ﬁbronectin ﬁbrillogenesis in
Tie2-silenced BECs.
Integrin-mediated regulation of actin cytoskeleton. We next
investigated whether b1-integrin was required for the change in
the cellular actin architecture observed in the Tie2-silenced BECs.
b1-integrin silencing did not affect the cortical actin cytoskeleton
of control cells, likely due incomplete b1-integrin silencing in
these cells. However, b1-integrin silencing was effective in
blocking the formation of the actin stress ﬁbres in the Tie2-
silenced BECs (Fig. 3a,b). Treatment with b1-integrin-blocking
antibodies (mAb13, 4 mgml 1), to more efﬁciently inhibit
b1-integrin function in BECs, disrupted both actin stress ﬁbres
and the cortical actin rim of Tie2-silenced and control cells,
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Figure 1 | Ang2 reduces endothelial monolayer integrity in Tie2-dependent and -independent manners. (a) BECs were transduced with scramble (Scr)
or Tie2 shRNA lentiviruses, ﬁxed and stained for ﬁlamentous actin (F-actin) and VE-cadherin. (b) BECs were transduced with Scr, Tie2, Tie1 or Ang2 shRNA
lentiviruses, and the cell lysates were analysed by western blotting using the indicated antibodies. (c) Quantiﬁcation of the percentage of cells displaying
actin stress ﬁbres (% of stress ﬁbreþ cells) (3 microscopic images/experiment, analysis of 60 cells/lentiviral transduction, n¼ 3 independent
experiments, P¼0.04, Dunnet’s test). (d) Quantiﬁcation of VE-cadherin area/nuclei in Scr or Tie2-silenced BECs (5 images/experiment, n¼ 3
independent experiments, P¼0.01, Dunnet’s test). (e) BECs seeded on ﬁbronectin-coated Transwell inserts were treated with anti-Ang2 antibody or
control hIg, and the GFP-expressing LNM-35 cancer cells transmigrated in 5 or 9 h were counted (percentage of transmigrated anti-Ang2 versus control
antibody-treated cells, n¼ 3 independent experiments, each performed in triplicate, P¼0.05 (5 h), P¼0.01 (9 h), Student’s T-test). (f) LLC-GFP cancer
cells transmigrated during 9 h through a BEC monolayer transduced with Scr or Tie2 shRNA lentiviruses were quantiﬁed as the GFP-positive area (n¼ 3
independent experiments, each in duplicate or triplicate, P¼0.007, Student’s T-test). (g) BECs were transduced with Scr, Tie2, Ang2 or Tie2þAng2
shRNA lentiviruses, ﬁxed and stained for F-actin. Quantiﬁcation of the percentage of cells displaying actin stress ﬁbres (5–7 microscopic images/
experiment, 500 cells/transduction analysed, n¼4 independent experiments, P¼0.001, Dunnet’s test). (h) Q-RT–PCR analysis of Ang1, Ang2 and Ang4
messenger RNA (mRNA) expression in BECs and HeLa cells. Shown is mRNA copy number in 10 ng total RNA. ND¼mRNA not detected. (i)
Representative images of Scr, Tie2, Ang2 and Tie2þAng2-silenced BECs. Mean and s.d. *Po0.05, **Po0.01, ***Po0.005. Scale bars, 20mm. Nuclear
40,6-diamidino-2-phenylindole stain. Confocal microscopic images.
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respectively (Fig. 3c; Supplementary Fig. 3b). These results sug-
gest that b1-integrin in the cell periphery maintains the endo-
thelial cortical actin cytoskeleton, and that Ang2 promotes
cytoskeletal changes via b1-integrin deposition in the central
elongated adhesions, which support actin stress ﬁbre formation.
To investigate the signalling mechanisms that contribute to
the Ang2-b1-integrin-induced cytoskeletal rearrangement in
endothelial cells, we analysed cell lysates using phosphoproteomic
proﬁling (Supplementary Fig. 5a). Silencing of Ang2 had no
signiﬁcant effect on the phosphorylation of intracellular signalling
proteins when compared with control shRNA-transduced cells.
However, the Tie2-silenced cells, but not cells co-silenced for Tie2
and Ang2 or Tie2 and b1-integrin, showed prominent phosphor-
ylation of Akt and Erk (Supplementary Fig. 5a,b). Akt is activated
by PI3K and indeed, treatment with the PI3K inhibitor LY294002
prevented the stress ﬁbre formation, rescuing the cortical actin
rim, but not VE-cadherin-positive cell junctions, in the Tie2-
silenced cells (Supplementary Fig. 5c). Similarly, inhibition of Rho
kinase activity reduced stress ﬁbres and promoted the formation
of cortical actin structures in the Tie2-silenced cells (see
Supplementary Fig. 5d,e).
In addition to b1-integrin, BECs express b3 and b5-integrins,
which together with the av-integrin, form RGD-binding
heterodimers (Fig. 3d). In contrast to b1-integrin, the avb3
heterodimer was more evenly distributed in BECs and enriched in
the cell–cell contacts in control, and to a lesser extent, in Tie2-
silenced BECs (Supplementary Fig. 3c). Integrin avb5 was
localized around the cell nucleus in conﬂuent BECs, in line with
previous results37, but was associated with cell adhesions at the
ends of actin stress ﬁbres in few Tie2-silenced cells
(Supplementary Fig. 3c). Silencing of av, b3 or b5-integrins did
not rescue the cortical actin structure in the Tie2-silenced cells
(Fig. 3e,f; Supplementary Fig. 3d–f). Furthermore, av- and
b3-integrin silencing resulted in disorganized cortical actin
(Fig. 3e,f; Supplementary Fig. 3e), in line with previous reports
implicating avb3 in the stabilization of the cortical actin
cytoskeleton in endothelial cells38,39. Taken together, these data
demonstrate that the cytoskeletal and junctional alterations
induced by Tie2 silencing in BECs are not dependent on
av-integrins, and instead rely speciﬁcally on b1-integrin function.
Ang2, but not Ang1, activates b1-integrin. Our results suggested
that when Tie2 levels are downregulated in endothelial cells, the
subsequent increase in the b1-integrin/Tie2 ratio induces a switch
to Ang2 signalling via b1-integrin. To investigate Ang2 signalling
in the absence of Tie2, we used the HeLa adenocarcinoma cell
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transduced with Scr or Tie2 shRNA lentiviruses in growth media containing ﬁbronectin-depleted serum. The cells were stained for F-actin and ﬁbronectin.
Nuclear Hoechst stain. Projections of confocal z-stacks. Scale bars, 20mm.
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line, which expresses b1 integrins, but essentially no Tie2 on the
cell surface (Supplementary Fig. 6a, endogenous Tie2 staining in
HeLa cells marked with an asterisk in Supplementary Fig. 7). Both
ectopic Ang2 expression (Supplementary Fig. 6b) and stimulation
with recombinant Ang2 (Fig. 4a; Supplementary Fig. 6c) resulted
in Ang2 deposition to speciﬁc cell–matrix adhesions, very close to
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is not detected in b1-integrin-silenced cells. (b) Western blot of Scr and b1-integrin-silenced BEC lysates using the indicated antibodies. (c) BECs were
transduced with Scr and Tie2 shRNA lentiviruses for 48 h, treated with control or b1-integrin-blocking antibodies (mab13) (10 mgml 1) during 32–48h
after transduction and stained for F-actin and active b1-integrin. Mab13 was detected with anti-rat secondary antibodies. (d) Integrin expression in BECs
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active b1-integrin, and this localization was signiﬁcantly inhibited
by b1-integrin-blocking antibodies, but not by treatment with
cilengitide40, a pentapeptide inhibitor of av-integrins (Fig. 4a,b;
Supplementary Fig. 6c). In contrast, b1-integrin-blocking
antibodies did not signiﬁcantly change the diffuse localization
of recombinant Ang1 in Ang1-stimulated cells (Supplementary
Fig. 6d). However, when Tie2 was ectopically expressed in HeLa
cells, Ang1 was detected in Tie2-positive cell–cell junctions, in
line with previous results13,41, whereas Ang2 localization to cell
adhesions occurred both in the presence and absence of ectopic
Tie2 or Tie1 (Supplementary Fig. 7). These results indicate that
Ang2 deposition in the HeLa-cell matrix is b1-integrin-
dependent, but Tie2 independent. Of note, in Ang2-stimulated
cells, active b1-integrin was localized to the basal surface, whereas
in unstimulated or Ang1-stimulated cells, b1-integrin was found
in focal adhesions in the cell periphery (Fig. 4a, quantiﬁed in
Fig. 4c; Supplementary Fig. 6d).
We next examined whether Ang2 is able to directly activate
b1-integrin. We used a sensitive cellular assay measuring the
binding of a recombinant ﬁbronectin fragment (FN7–10) to
activated endogenous a5b1 integrin in Chinese hamster ovary
(CHO) cells relative to total surface b1-integrin expression42,43.
In this assay, Ang2 enhanced CHO-cell binding to ﬁbronectin in
a dose-dependent manner, indicative of increased b1-integrin
activation (Fig. 4d,e). Of note, a 150 nM (10mgml 1)
concentration of Ang2 stimulated FN7–10 binding to CHO
cells equally well as the ectopic expression of the talin head
domain, a prominent inside-out activator of b1-integrin44. In
contrast, Ang1 did not induce b1-integrin activation, even when
used in higher concentrations (Fig. 4d,e). Ang2 also directly
bound to the b1-integrin subunit in an enzyme-linked
immunosorbent assay (ELISA) (Fig. 4f), suggesting that Ang2
activates b1-integrin via a direct interaction.
To investigate the mechanism of Ang2-mediated b1-integrin
activation, we created a chimeric Ang2–Ang1 growth factor
containing the N-terminal Ang2 superclustering and coiled-coil
domains fused to the Ang1 C-terminal ﬁbrinogen-like domain
(FLD) (Ang2–Ang1), as well as the opposite Ang1–Ang2 chimera
with the Ang1 N-terminal domain attached to the Ang2 FLD
(Fig. 4g). The Ang2–Ang1 chimera was localized in cell–matrix
adhesions, similarly to full-length Ang2, whereas the Ang1–Ang2
protein showed more diffuse localization when expressed in HeLa
cells (Supplementary Fig. 6b). In addition, Ang2–Ang1 activated
b1-integrin to the same extent as Ang2, whereas the Ang1–Ang2
chimera had no effect (Fig. 4h). Furthermore, recombinant Ang1
and Ang2 FLDs (residues 245–497 and 242–496, respectively)
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Figure 4 | The N-terminal domain of Ang2, but not of Ang1, activates b1-integrin. (a–c) HeLa cells seeded on ﬁbronectin were stimulated with 4mgml 1
rhAng2 (a,b) or rhAng1 (c) for 30min, or pretreated with b1-integrin-blocking antibody (4 mgml 1 mab13, a,b) or cilengitide (10 mM, b) for 5min, and then
further stimulated for 30min with rhAng2. The cells were stained for active b1-integrin (12G10) and for His-tag (a,c) or Ang2 (b). (b) Ang2-positive matrix
adhesions were analysed from 7 (mAb13) or 10 (cilengitide) microscopic images/experiment (total of 500 cells/mAb13 treatment and 320 cells/
cilengitide treatment, n¼ 3 for mAb13, for cilengitide a representative experiment is shown, repeated three times) P¼0.03 for mAb13 and P¼0.496 for
cilengitide, Student’s T-test. (c) Active b1-integrin was quantiﬁed from 7 microscopic images/experiment, total of 350 cells/treatment analysed, n¼ 3,
P¼0.04 for control versus Ang2, P¼0.01 for Ang2 versus Ang1, P¼0.99 for control versus Ang1, Dunnet’s test. (d) CHO cells were incubated with
ﬂuorescently labelled ﬁbronectin fragment (FN7–10) and with various concentrations of rhAng2 or rhAng1, as indicated. FN7–10 binding to CHO cells was
quantiﬁed using ﬂuorescence-activated cell sorting, and normalized to total a5b1 levels, as explained in the methods. P¼0.0004 for 10mgml 1 (150 nM)
(n¼ 3) and P¼0.007 for 5 mgml 1 (75 nM) (n¼ 3) concentration of rhAng2 versus FN7–10 only, Dunnet’s test. (e) CHO cells were treated with the
indicated concentrations of rhAng1 or rhAng2, and integrin activation measured as in d. (f) Binding of Ang2–Flag to biotinylated b1-integrin ectodomain
was measured in triplicate using ELISA, a representative experiment of two independent experiments is shown. (g,h) CHO cells transduced with a control
plasmid, or plasmids encoding for ﬂag-tagged Ang2, Ang1–Ang2 (Ang1–2) or Ang2–Ang1 (Ang2–1) chimeric proteins (schematic structures are shown in g)
were incubated with FN7–10 and, where indicated, with 10mgml 1 rhAng2. FN7–10 binding to CHO cells was quantiﬁed as in d. P¼0.004 for rhAng2,
P¼0.002 for Ang2–Flag, P¼0.001 for Ang2–1–Flag versus FN only, (n¼ 3, Dunnet’s test). Mean and s.d. *Po0.05, **Po0.01, ***Po0.005. Nuclear
Hoechst stain. Projections of confocal z-stacks. Scale bar, 20mm.
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fused to the Fc region of human immunoglobulin G failed to
activate b1-integrin (concentration range 10–50mgml 1,
Supplementary Fig. 6e), whereas expression of the N-terminal
domain of Ang2, but not of Ang1, increased the formation of
stress ﬁbres in BECs (Supplementary Fig. 6f). These results
suggested that the Ang2 N-terminal domain promotes b1-integ-
rin activation, leading to Ang2 deposition in cell–matrix
adhesions in a b1-integrin-dependent manner.
To investigate Tie2 function in Ang2-b1-integrin signalling, we
used murine Tie2 receptor complementation in Tie2-silenced
BECs. For this, we transduced Tie2-silenced BECs with a
retroviral construct expressing the membrane-bound ectodomain
of murine Tie2 (mTie2-ECD), which lacks kinase activity (Fig. 5).
mTie2-ECD increased the cortical actin cytoskeleton in Tie2-
silenced cells, whereas a membrane-bound GFP control protein
did not (Fig. 5a,b). Furthermore, Ang2-mediated integrin
activation was completely blocked by mTie2-ECD expression,
as measured by the ﬁbronectin fragment-binding assay (Fig. 5c).
These results indicated that Tie2 captures Ang2 at the endothelial
cell surface to inhibit Ang2 signalling via b1-integrin. Further-
more, Tie2 kinase activity was not required for stabilization of the
cortical actin cytoskeleton in endothelial cells.
Changes in the aortic endothelium of Ang2 transgenic mice. In
our previous studies, induced expression of murine Ang2 in the
endothelium of double-transgenic mice (VE-cadherin-tTA (VEC-
tTA)/Tet-OS-Ang2 mice; VEC-tTA/Ang2 for short) resulted in
increased lung metastasis, and marked capillary changes in vessels
adjacent to extravasated tumour cells, including endothelial cell-
basement membrane detachment, reduced endothelial cell–cell
junctions and gaps between the endothelial cells19. These changes
were much less prominent in wild-type (WT) tumour-bearing
littermates19, suggesting that increased Ang2 levels aggravated
endothelial destablization induced by the tumour cells in the lungs.
We therefore investigated possible vascular changes that may
predispose to compromised barrier function in transgenic mice, in
which Ang2 expression was induced after birth. Transgenic Ang2
expression by endothelial cells resulted in elevated systemic Ang2
levels in this model (Supplementary Fig. 8a). To investigate the
effects of Ang2 on endothelial integrity in quiescent vessels, we
analysed en face prepared mouse aorta using whole-mount staining
for VE-cadherin, CD31, active b1-integrin, ﬁlamentous actin and
Tie2 (Figs 6 and 7; Supplementary Fig. 8b). The overall VE-
cadherin and CD31 patterns in the cell–cell contacts of WT mouse
aorta vary from narrow linear lining in the high-ﬂow regions in the
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ascending aorta (area 1a) and the outer curvature of the aortic
arch45, to a more irregular VE-cadherin staining in the descending
part (area2 and 3), which is subject to lower-ﬂow forces (Fig. 6a–c).
In all regions analysed, the VEC-tTA/Ang2 mice showed a more
irregular VE-cadherin staining, when compared to WT or single-
transgenic littermates with interdigitating structures emerging at
cell–cell junctions. These ﬁnger-like structures were also stained by
the CD31 antibodies (Fig. 6d). Interestingly, in the VEC-tTA/Ang2
mice, active b1-integrin was localized in central elongated
adhesions in the aortic endothelial cells unlike in WT mice,
where active b1-integrin-positive adhesions were weakly detected
in the cell centre (Fig. 6d). Furthermore, cortical actin staining co-
localized with VE-cadherin staining in the aortic endothelium of
WT mice, whereas in the VEC-tTA/Ang2 mice, central actin ﬁbres
were detected, but they did not overlap with VE-cadherin
(see Supplementary Fig. 8b). Notably, Tie2 was enriched in the
cell-cell junctions, especially in the high-ﬂow regions of the
ascending aorta (area 1a) and in the outer curvature of the arch,
but this was reduced in VEC-tTA/Ang2 mice (Fig. 7). These results
indicate that elevated Ang2 levels reduce junctional Tie2
localization and alter b1-integrin activation and F-actin and VE-
cadherin localization in the otherwise quiescent mouse aortic
endothelium, recapitulating in vivo the effects of increased Ang2-
b1-integrin signalling observed in Tie2-silenced cultured
endothelial cells.
Here, we identify Ang2 as an activator of b1-integrin in
endothelial and non-endothelial cells, and in the vessel endothe-
lium in vivo. Our results show that the autocrine, endothelial cell-
secreted Ang2 has profound signalling functions, which do not
require Tie2 kinase activity or the context-dependent Tie2
antagonist activity of Ang2. The membrane-bound ectodomain
of Tie2 was sufﬁcient to completely block Ang2-induced
b1-integrin activation, and to compensate for the silencing of
endothelial Tie2 in BECs, suggesting that Tie2, by acting as a
ligand trap, inhibited endothelial Ang2-b1-integrin signalling.
The N-terminal super-clustering and coiled-coil domains of
Ang2 promoted b1-integrin activation, whereas the C-terminal
angiopoietin-FLD-Fc fusion proteins did not, implying a unique
Ang2 N-terminal-dependent role in the regulation of b1-integrin
function. Ang2 bound directly to the b1-integrin subunit,
suggesting a direct activation mechanism of b1-integrin hetero-
dimers. However, our results do not rule out additional
interactions with b1-integrin, mediated via the C-terminal
domains of Ang2 or Ang1.
Integrin a5b1 and avb3 have been previously reported to
converge on signalling pathways mediated by Ang1-Tie2 and
Ang2-Tie2 complexes, respectively, resulting in different cellular
outcomes in endothelial cells33,34. Our results differentiating
between Ang1- and Ang2-mediated b1-integrin activation in the
absence of Tie2 are in line with Ang2-integrin signalling in the
endothelial tip cells, which express high Ang2 but low Tie2
levels27. Thus, besides the differential regulation of Tie2
phosphorylation6,13,46–48, integrin activation is a major
dichotomous difference between the signalling mechanisms of
Ang1 and Ang2. This fundamental ﬁnding should explain some
of the perplexing and context-dependent functions of Ang2.
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Our results demonstrated that b1-integrin has a dual,
subcellular localization-dependent function in the maintenance
of the endothelial actin cytoskeleton: b1-integrin in the cell
periphery maintained the cortical actin cytoskeleton, whereas
centrally located b1-integrin-containing elongated adhesions
were associated with actin stress ﬁbres in the Tie2-silenced
endothelial cells. Importantly, the localization of active b1-integ-
rin in the elongated adhesions was dependent on Ang2. A recent
report demonstrated that activation of b1-integrin due to loss of
its inhibitor, ICAP-1, in human cerebral cavernous malforma-
tions, results in b1-integrin deposition in ﬁbrillar adhesions,
increased actin stress ﬁbres and reduced endothelial barrier
function35, suggesting that increased b1-integrin activity
destabilizes intercellular junctions via increased cell contractility
and aberrant pericellular matrix remodelling, in line with our
results. Integrins avb3 and avb5 have been reported to
reciprocally regulate the endothelial actin cytoskeleton and
contribute to endothelial and pulmonary vascular barrier
function in a positive and a negative manner, respectively37,39.
We found that av- or b3-integrin silencing resulted in increased
stress ﬁbre formation and loss of endothelial cortical actin
cytoskeleton, in line with previous results39. However, avb3 or
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Figure 7 | Localization of Tie2 in the aortic endothelium of wild-type and VEC-tTA/Ang2 mice. Representative en face stainings of VE-cadherin and
Tie2 in VEC-tTA/Ang2 transgenic or WT littermate mouse aortic endothelium from the areas indicated, n¼ 3 VEC-tTA/Ang2 and n¼4 WTmice.
Projections of confocal z-stacks. Scale bar, 20mm, in magniﬁcation 10mm.
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avb5-integrins were not required for stress ﬁbre formation in the
Tie2-silenced cells, although the reduced junctional localization of
avb3-integrin and increased stress ﬁbre localization of avb5 may
further promote the destabilized phenotype of these cells.
Our results from the VEC-tTA/Ang2 transgenic mice indicate
that high Ang2 levels regulate endothelial b1-integrin-containing
cell-basement membrane adhesion sites, the actin cell cytoskele-
ton and endothelial cell–cell junctions. Although the mechanism
remains to be fully elucidated, our results show that Tie2,
especially in the cell junctions, is reduced in the VEC-tTA/Ang2
mice compared with WT mice, which may sensitize the
endothelium towards Ang2-b1-integrin signalling. Collectively,
these changes should lead to endothelial cell–cell junctions that
are predisposed to undergo further destabilization under stress
when the endothelium is exposed to, for example, inﬂammatory
cytokines or extravasating tumour cells12,14,19,32. This is in line
with previous results of the function of Tie2 during endothelial
dysfunction, showing that heterozygous Tie2 mice are more
susceptible to endotoxin-induced lung injury, and that
Tie2 levels are downregulated during septic shock10,49.
Furthermore, reduced Tie2 expression was recently associated
with susceptibility to vascular complications induced by
haemorrhagic Ebola virus infection in mice50. We found that
antibodies blocking the Ang2–Tie2 interaction reduced tumour
cell transendothelial migration, in line with previously published
in vivo data19. On the other hand, autocrine Ang2-b1-integrin
pathway activation in Tie2-silenced BECs resulted in increased
transmigration of tumour cells. High Ang2 levels and decreased
Tie2 levels may augment Ang2-b1-integrin signalling, endothelial
b1-integrin activation and cellular tension, eventually resulting in
reduced barrier function. In summary, our results establish Ang2
as an activator of b1-integrin and call for a better understanding
of the Ang2-b1-integrin pathway, when blocking reagents
targeting Ang2 are developed for the treatment of human
diseases, including cancer.
Methods
Reagents and cell culture. Human dermal microvascular blood endothelial cells
(BECs, PromoCell, Heidelberg, Germany, or Lonza, Basel, Switzerland) were
maintained in endothelial basal medium (ECBM, PromoCell or EBM-2) with fetal
bovine serum (FBS) and growth supplements, provided by the manufacturers, on
1 mgml 1 ﬁbronectin-coated culture plates. CHO, HeLa and LLC cells (ATCC)
were maintained in Dulbecco’s modiﬁed Eagle’s medium (DMEM) (Lonza), and
NCI-H460-N15 ATCC (LNM-35 for short) in RPMI (Lonza), all media supple-
mented with 2mM L-glutamine, penicillin (100Uml 1), streptomycin
(100 mgml 1) and 10% FBS. LNM-35 and LLC cells were made ﬂuorescent (LNM-
35-GFP) by the expression of the GFP19. Packaging cell lines 293-GPG VSV-G51
(growth medium: DMEM glucose 4.5 g l 1 supplemented with 10% FBS, 1%
glutamine, 0.2% penicillin, 0.2% streptomycin, 0.2% puromycin, 0.6% neomycin
and 1 mgml 1 tetracycline) and 293FT (growth and transduction medium: DMEM
glucose 4.5 g l 1 supplemented with 10% FBS, 1% L-glutamine, 0.2% penicillin and
0.2% streptomycin) were transduced for retrovirus (transduction medium: DMEM
glucose 4.5 g l 1, 20mM HEPES, supplemented with 10% FBS, 1%
L-glutamine, 0.2% penicillin and 0.2% streptomycin) and lentivirus production
with Fugene 6 (Roche, Basel, Switzerland), respectively. Retroviral constructs were
cloned into the pMXs vector (generous gift from Dr Kitamura, University of
Tokyo, Japan). For angiopoietin stimulations, the HeLa cells were starved for 2 h in
2% FBS–DMEM, and stimulated in the starvation medium using 60 nM
(4mgml 1) rhAng1 and rhAng2 (R&D Systems, Minneapolis, MN) for 30min.
mAb13 (BD Biosciences, San Jose, CA) was used at 4 mgml 1.
The following antibodies were used at dilution 1:100 for immunoﬂuorescence
(IF) staining, unless otherwise indicated: anti-hTie1 (AF619), anti-hTie2 (AF313,
WB 1:4,000), anti-m/r-Tie2 (AF762, 1:1,000), anti-hAng2 (AF623) (R&D Systems),
anti-mTie2/Tek4 (cat. 95–585, 1:80, Millipore, Billerica, MA), anti-hVE-cadherin
(1:200, cat. 555661, Pharmingen, BD Biosciences; cat. 2500, Cell Signaling
Technology, Danvers, MA), anti-mVE-cadherin (555289; BD Biosciences or 14–
1441, eBioscience, San Diego, CA), anti-His-tag (1:40, 2365, Cell Signaling
Technology), anti-Flag (1:1,000, F3648, M2, Sigma-Aldrich, St Louis, MO), anti-
ﬁbronectin (F3648, Sigma-Aldrich), anti-b1-integrin (1:30)52, mab12G10 (1:300,
Abcam, Cambridge, UK), mab2252 (Merck Millipore) and anti-hamster a5b1
(1:50, PB1, developed by Brown and Juliano53 and obtained from the
Developmental Studies Hybridoma Bank developed under the auspices of the
NICHD and maintained by the University of Iowa), anti-mouse CD31 (1:2,000,
Mab1398Z, Millipore), anti-avb3 (1:40, mab1976, Millipore), Alexa-488, Alexa-
594, Alexa-647-conjugated secondary antibodies (1:300, Life Technologies,
Carlsbad, CA) and anti-hamster FITC (Jackson Immunoresearch, Westgrove, PA).
Filamentous actin was stained using Texas red or Alexa-488-conjugated phalloidin
(1:200, Invitrogen, Life Technologies). For immunoblotting, cells were lysed in
M-PER lysis buffer (Pierce)54. Uncropped immunoblots and larger blot areas are
presented in the Supplementary Fig. 9.
Q-RT–PCR. Total RNA was isolated using the RNA NucleoSpin II Kit (Macherey-
Nagel), reverse transcribed to complementary DNA (cDNA) using the SuperScript
VILO cDNA Synthesis Kit (Invitrogen) or the RT2 First Strand Kit (Qiagen) and
used (10 ng RNA eqvivalent/reaction) for Q-RT–PCR. Primers used were: Ang1
(50-aacatgggcaatgtgcctacactt-30 and 50-cattctgctgtatctgggccatct-30 or 50-acgtg-
gaaccggatttctct-30 and 50-tttagtacctgggtctcaacatct-30), Ang2 (50-cagattttggacca-
gaccagtga-30 and 50-tcaatgatggaattttgcttgga-30), Ang4 (50-atccagcgccgtgagaatg-30
and 50-aaatgttcgtactgggcatagg-30 or 50-caggactgtgcagagatcca-30 and 50-
tctccgaagccctgtttgta-30). An estimate of Ang2 messenger RNA copy number was
calculated based on control samples of known Ang2 cDNA concentrations.
Integrin expression was analysed using the RT2 proﬁler Array Wound Healing
(Qiagen).
shRNA and siRNA silencing of cells. Cells were transduced with shRNA lenti-
virus or retrovirus particles in the presence of 0.1% Polybrene (Sigma-Aldrich) for
48 h. For small interfering RNA (siRNA) silencing of Tie2, BECs were starved
overnight in 1% FBS endothelial medium, without supplements, and transduced
twice for 24 h on subsequent days, with siRNA against Tie2 or scramble sequences
(SC-36678, Santa Cruz Biotechnologies) using Oligofectamin (Invitrogen). shRNA
lentiviruses from the TRC1 library were used together with packaging plasmids
pCMVg and pCMVdelta8.9. Unless otherwise indicated, shRNA#4 was used to
silence Tie2, and shRNA#27 for Ang2 silencing.
Immunoﬂuorescence staining. Cells were ﬁxed for 10–15min in 4% para-
formaldehyde (PFA)–PBS, washed 3 5min with PBS, permeabilized 5min with
0.1–0.2% Triton X-100 in PBS, blocked 10min in 1% bovine serum albumin
(BSA)–PBS, and incubated 30min with primary antibodies in 1% BSA–PBS,
washed with PBS, blocked and subsequently incubated for 30min with secondary
antibodies at room temperature, washed with PBS and mounted using DAPI-
Vectashield (Vector laboratories Inc, CA, USA) or Mowiol-Dabco (Sigma-Aldrich);
nuclei were prestained with Hoechst (Sigma-Aldrich).
Quantiﬁcation of microscopic images. Images were captured using a Zeiss digital
Axiocam camera connected to a Zeiss Axioplan 2 microscope and a  40 oil
objective, or using a laser scanning confocal microscope (Zeiss LSM 780 or Zeiss
LSM 5 Duo) with a  63 or a  40 oil objective. Three-dimensional projections
were digitally reconstructed from confocal z-stacks. Stress ﬁbre-positive cells were
identiﬁed by the presence of stress ﬁbres extending across the longitudinal cell axis,
while cells with cortical actin showed no actin staining in the cell centre sur-
rounding the nucleus. Stress ﬁbre-positive cells were imaged using an epi-
ﬂuorescent microscope with a  40 objective and counted from 3–7 randomly
selected epiﬂuorescence micrographs per experiment. In each image, the number of
stress ﬁbre-positive cells was divided by the total number of cells based on nuclear
staining. Two independent investigators counted the stress ﬁbre-positive cells in an
investigator-blinded fashion. Quantiﬁcation of the VE-cadherin area was per-
formed from similarly acquired epiﬂuorescence micrographs and the Image J
software (http://imagej.nih.gov/ij/).
Adhesion assay. BECs were transduced with scramble or Tie2 shRNA lentiviruses
for 48 h. Cells were detached with trypsin-EDTA and let to recover in EBM-2
complete medium for 30min. A total of 15,000 cells were seeded on each coverslip,
precoated with 10mgml 1 of ﬁbronectin for 1 h and let to adhere for 45min.
Coverslips were ﬁxed and subjected to immunoﬂuorescence staining. For quanti-
ﬁcation of increased adhesion maturation, pixel area of active integrin b1-positive
adhesion structures was quantiﬁed in the central 50% of the total cell area and
normalized to total area in the central 50% of the cell (see squares in Fig. 2b).
Tie2 complementation assay. BECs were grown to 50% conﬂuence and trans-
duced for 24 h with lentiviral shRNA against Tie2 or scramble sequences. The cells
were additionally transduced with retroviruses coding for membrane-anchored
mouse Tie2 ectodomain (mTie2-ECD) or membrane-anchored GFP for another
24 h. Cells were ﬁxed and mTie2-ECD-transduced samples were stained using
speciﬁed antibodies against mouse Tie2. mTie2-ECD- or GFP-positive cells with
stress ﬁbres were quantiﬁed from three independent experiments, seven epi-
ﬂuorescence micrographs/experiment, imaged using  40 objective.
Tumour cell–endothelial cell transmigration assay. Tumour cell transmigration
across an endothelial cell monolayer was performed using Transwell chambers
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(6.5mm insert diameter, 8 mm pore size, Corning Life Sciences, NY, USA). BECs
(100,000), transduced with Tie2 or scramble shRNA lentiviruses, were seeded on
the upper compartment overnight, after which 100,000 LLC-GFP were applied on
top of the conﬂuent endothelial monolayer for 9 h, with complete growth media in
both chambers. Inserts were ﬁxed in 4% PFA–PBS and mounted onto glass slides.
Five microscopic ﬁelds per insert were imaged at  40 magniﬁcation using the
Zeiss Axioplan microscope, and transmigrated cells were quantiﬁed from the
bottom of the ﬁlter as the GFP-positive area using the ImageJ software.
Alternatively, 100,000 LNM-35-GFP cells were applied on top of the conﬂuent
BEC monolayer for 5 or 9 h and treated with control or anti-Ang2 antibody
blocking the Ang2–Tie2 interaction. The inserts were ﬁxed and imaged using the
Zeiss AxioVert200 connected to Zeiss AxioCam with  10 magniﬁcation from the
centre of the bottom of the insert. GFP-positive LNM-35 cells were counted
manually from three independent experiments, each performed as triplicate.
Integrin activation assay. For testing chimeric angiopoietin proteins, CHO cells
were left untreated or transfected at 25–30% conﬂuency with 5,000 ng of plasmid
constructs for Ang1–Ang2–Flag, Ang2–Flag or Ang2–Ang1–Flag with lipofecta-
mine 2000 (Life Technologies) preincubated with Opti-MEM (according to the
manufacturer’s instructions). After 24 h, the transduction mixture was changed to
serum-free alpha-MEM (Minimum Essential Media) (2mM L-glutamine). The next
day, part of the culture medium was collected, the cells were detached with HiQtase
in serum-free alpha-MEM, spun and resuspended to respective culture mediums
collected earlier. Each sample was subsequently treated with 1% Alexa-647-con-
jugated ﬁbronectin fragment (repeats 7–10, FN7–10) and 10% anti-hamster a5b1
antibody (PB1), recognizing total a5b1 irrespectively of a5b1 activation state. For
testing of recombinant proteins, CHO cells were collected as mentioned with
HiQtase in serum-free alpha-MEM, and preincubated 30min with various con-
centrations of rhAng2, rhAng1 or EDTA, treated with 1% Alexa-647-conjugated
ﬁbronectin fragment, incubated for 30 min at room temperature, washed with PBS,
ﬁxed with 4% PFA for 15min, washed and stained with the total a5b1 antibody.
All samples were then stained with Alexa-488-conjugated anti-mouse secondary
antibody to detect the anti-a5b1 antibody and analysed using ﬂuorescence-acti-
vated cell sorting. The results were expressed as the activation index of b1-integrin:
the ratio between the activated and total b1-integrin. This was calculated by
measuring integrin activity (with Alexa-647-labelled ﬁbronectin fragment binding)
against a background signal (labelled FN-binding in the presence of inactivating
EDTA) normalized against total cellular b1-integrin.
Fibronectin matrix remodelling. BECs were plated on vitronectin (Invitrogen)-
coated coverslips and transduced with scramble or shTie2 lentiviruses. Cells were
maintained in endothelial growth medium, supplemented with serum, depleted for
ﬁbronectin by rotating the serum with gelatine sepharose (GE Healthcare, Fairﬁeld,
CT, USA) two times for 1 h, and spinning the sepharose containing serum using
Micro Bio-Spin chromatography columns (Bio-Rad, Hercules, CA, USA). Deple-
tion of ﬁbronectin was conﬁrmed using western blotting.
Elisa assay for b1-integrin binding to Ang2. Maxisorp plate was coated with
anti-Flag antibody (13mgml 1) in Hepes-buffered saline (HBS) containing 1mM
CaCl2, 20ml per well and incubated at room temperature for 4 h. The wells were
washed twice with HBS, followed by incubation with 10 ml of concentrated con-
ditioned media from control or Ang2-expressing 293 T cells in 50 ml HBS overnight
at room temperature. The wells were washed twice, blocked with 2% BSA for 2 h at
room temperature, washed twice and incubated with 1:5 dilutions of biotinylated
b1-integrin ectodomain (ECD), 20 ml per well, for 4 h at room temperature. The
wells were washed twice, incubated overnight at þ 4 C with Streptavidin-HRP
(Dako) in 2% BSA, 1:4,000 dilution, washed 3 and followed by incubation with
the horseradish peroxidase substrate. Absorbance was measured using the Multi-
scan Ascent spectrophotometer (Thermo Labsystems) at 450 nm.
Expression vector cloning. Angiopoietin chimeras Ang1–Ang2–Flag and Ang2–
Ang1–Flag were constructed in the following fashion: the angiopoietin FLD and the
adjacent N-terminal linker region (amino acids R262-F498 in Ang1; K249-F496 in
Ang2) were changed between Ang1 and Ang2 using two-step PCR and cloned into
the pMXS vector. The constructs were tagged with a Flag-peptide-coding sequence
(DYKDDDDK), which was attached directly to the chimeric angiopoietin C ter-
minus, followed by a stop codon. Ang2 and Ang2–Ang1 contained the native Ang2
signal sequences, whereas Ang1 and Ang1–Ang2 were expressed under the Igk
light-chain signal sequence. The N-terminal Ang1 (amino acids 1–261) and Ang2
(amino acids 1–248) forms with C-terminal Flag-tag were cloned by PCR into the
pMXs vector. mTie2-ECD was cloned by PCR into the pMXs vector, resulting in a
deletion of the intracellular I824-A1124 amino acids in mTie2. A membrane-
bound form of enhanced GFP was created by attaching a myristoylation and
palmitoylation sequence from the Lyn kinase (MGCIKSKRKDNLNDDGVD)55 to
the enhanced GFP N terminus by PCR. The resulting PCR fragment was inserted
in pMXs.
Animal models. Mice were maintained in the Laboratory Animal Centre of the
University of Helsinki. The National Animal Experiment Board in Finland
approved animal experiments used in this study. We used the VEC-tTA/Tet-OS-
Ang2 mouse line, which expresses mouse Ang2 under an inducible endothelial cell
promoter19. The driver VEC-tTA and responder transgenic mouse lines were bred
together to obtain double-transgenic VEC-tTA/Tet-OS-Ang2 offspring. To
overcome the embryonic lethality due to endothelial Ang2 overexpression in
double-transgenic embryos, Ang2 expression was repressed during the entire
pregnancy. Tetracycline (Sigma-Aldrich) at 2mgml 1 in 5% sucrose was added to
the drinking water of pregnant females, starting at the time of mating and until
birth, when Ang2 expression was induced by discontinuation of tetracycline
administration. Single-transgenic or WT littermates were used as controls for
double-transgenic mice, both designated as WT. None of the control mice
displayed any obvious phenotype.
En face preparation and whole-mount staining of mouse aorta. For en face
preparation of aortas, 2–8-month-old mice were anaesthetized with intraperitoneal
injections of xylazine (10mg kg 1) and ketamine (80mg kg 1) and perfusion
ﬁxed with 1% PFA–PBS. Aortas were ﬁxed for 1 h in 1% PFA–PBS, washed with
PBS and blocked with donkey immunomix (5% donkey serum, 0.2% BSA, 0.3%
TritonX-100 and 0.05% sodium azide in Dulbecco’s PBS) for 1 h at room tem-
perature. Whole-mount staining was performed using indicated primary antibodies
for 48 hþ 4, followed by extensive washing using 0.3%-TritonX-100–PBS at room
temperature, incubation with secondary antibodies for 16 h, washing and post-
ﬁxing of the samples. The aortas were mounted in DAPI-Vectashield and z-stacks
were obtained using Zeiss LSM 780 and a  63 oil objective. Maximal projections
of VE-cadherin-positive stacks were used for VE-cadherin quantiﬁcation.
Statistical tests. Student’s t-test (two tailed, unequal variance) was used for
pairwise comparisons, and Dunnet’s test for multiple comparison analysis.
A P value o0.05 was considered statistically signiﬁcant.
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